Patna/Vaishali District : From this day on, treatment for kala azar will only take two hours. Single-dose liposomal amphotericin B, commonly referred to as Sd LAmB, has now been made available in select primary health centres in Bihar as the preferred treatment for kala azar (visceral leishmaniasis – VL). Bihar is one of the states in India where kala azar is highly endemic.
Doctors Without Borders/Médecins Sans Frontières (MSF) extends its full support to the government of Bihar in implementing the new treatment protocol of administering single-dose (10mg/kg) LAmB as the preferred first-line medicine to patients diagnosed with kala azar.
This new treatment programme is now available in select government health facilities in Bihar. The use of single-dose LAmB is a shift from the previous treatment protocol of Miltefosine which needed to be administered orally over a period of 28 days. Due to the distance to health facilities apart from climatic, social and economic factors, the number of people unable to follow the treatment for 28 days has been high. Single-dose LAmB is an effective treatment administered through intravenous infusion, which will be given to the patients over a two-hour period. This makes LAmB a more patient-friendly drug as a single point of care that can be given to all categories of patients, including pregnant women and young children and can be administered at different healthcare levels (local health centres and hospitals).
State Programme Officer, Shri M.P. Sharma said “Although the roll out of single dose AmBisome will be done in phases; by next year this new treatment will be made available free of cost in all the 33 endemic districts in Bihar. The SPO was accompanied by the District Malaria Officer, Dr. Anil Kumar Sinha, Dr. R.N. Pandey, RMRI and Dr. Seema Saroj, Medical Officer in-charge of Vaishali primary health centre. Dr. Pandey said that regular spraying and monitoring of spraying activities is very important in eliminating the disease. He also requested MSF to train the MoH medical staff so that diagonosis and treatment of kala azar can be done effectively. Representatives from Drugs for Neglected Diseases Initiative (DNDi) were also present.
Gradually, all local health centres in the most endemic districts of Bihar, Jharkhand, West Bengal and Uttar Pradesh will be able to diagnose and treat kala azar patients using single-dose LAmB. This paves the way for providing safer treatment for kala azar and towards achieving elimination by reducing the annual incidence to less than one case per 10,000 at the block level.
Transmitted by the bite of a sand fly, kala azar is a vector-borne disease, endemic in 76 countries around the world. Typically, the disease thrives in impoverished areas and is almost always fatal if left untreated. In India, Bihar is the epicentre of kala azar where 33 out of 38 districts are affected. The population at risk is nearly 35 million in approximately 11,500 villages spread over 429 provincial blocks.
MSF has been on the frontline of fighting kala azar in Bihar since 2007, and has treated, free of charge, more than 11,000 patients with LAmB to date and has achieved high cure rate results. The organisation extends its support to the Ministry of Health and Family Welfare (MoHFW), the National Vector Borne Disease Control Programme (NVBDCP), the Rajendra Memorial Research Institute (RMRI), and the Kalacore consortium, in the drive to eliminate kala azar and contribute to improving the health status of at-risk populations living in the endemic areas in India.
Notes to the editor:
· Single-dose LAmB, will be provided free of charge at all levels of health care in places where KA is highly endemic.
· Currently, MSF supports a 50-bed kala azar ward inside the Sadar District Hospital in Hajipur, and five primary health centres (PHCs) in Goraul, Vaishali, Mahua, Mahnar and Raghapur, where the single-dose LAmB is either available or will be made available in the near future. See more at: /access-kala-azar-treatment-public-healthcare-system-must-be-scaled#sthash.OjgaPycd.dpuf